Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker. Nature Communications , 2024; 15 (1) DOI: 10.1038/s41467-024-54129-w Cite This Page : ...
Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain ...
Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain ...
On the basis of these results, the researchers propose a molecular stratification of glioblastoma consisting of four clinically relevant tumor subtypes—classical, mesenchymal, proneural and neural.
A new study identifies key genetic vulnerabilities in glioblastoma stem cells, revealing subtype-specific dependencies that ...
Despite the progress in our understanding of the process of angiogenesis and the potential of targeting these processes for the treatment of GBM, many challenges remain. Considerations regarding ...
Epigenetic therapy potentiates transposable element transcription to create tumor-enriched antigens in glioblastoma cells. Nature Genetics , 2024; 56 (9): 1903 DOI: 10.1038/s41588-024-01880-x Cite ...
[27] In a Phase II study of cediranib in patients with recurrent GBM, the proportion of patients alive and progression free at 6 months was 25.8%. MRI partial responses were seen in 56.7% of ...
A Ludwig Cancer Research study has discovered that recurrent tumors of the aggressive brain cancer glioblastoma multiforme (GBM) grow out of the fibrous scars of malignant predecessors destroyed ...
It is currently under development to address several serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), a particularly aggressive and incurable form of brain cancer.